Covering: Biology - Neuroscience - MedicineCovering: Biology - Neuroscience - Medicine
All explained papers

Nature Medicine, 2026 Aug 6 · 6 min read

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial

Psilocybin is a psychedelic compound found in certain mushrooms. For most of the last sixty years it sat on Schedule I in the United States, meaning the government classed it as having no medical use and a high potential for abuse. A growing body of clinical trials has challenged that view. Now a randomized controlled trial in Nature Medicine reports on psilocybin-assisted therapy for treatment-resistant depression, with one difference from earlier trials: it was run in a public healthcare setting.

That setting matters. Earlier landmark trials, including those at Imperial College London and Johns Hopkins, took place in academic research centers with carefully chosen patients, extensive screening and well-funded teams. Those settings show whether something can work under ideal conditions. Whether it works in a real health system, with its limits and its ordinary patients, is a different question. This paper is an important step toward showing the therapy is not only effective but could be delivered outside research enclaves.

Major depressive disorder is one of the leading causes of disability worldwide. In its severe form it brings persistent low mood, loss of interest in things once enjoyed, slowed thinking, fatigue, disrupted sleep and appetite, and sometimes thoughts of suicide. The usual treatment is antidepressant medication, and most patients respond to one drug or another tried in turn.

Treatment-resistant depression is depression that has not responded to at least two proper courses of antidepressants at the right dose and for long enough. Depending on the exact definition, roughly fifteen to thirty percent of people with major depression fall into this group.

Their options are limited and imperfect. They include trying more drug classes; electroconvulsive therapy, which works but is hard to access and not widely accepted; transcranial magnetic stimulation; and ketamine or its relative esketamine, which the FDA approved for treatment-resistant depression in 2019. None works for everyone, and for many of these patients real relief stays out of reach. That is the gap psilocybin research is trying to fill.

In the body, psilocybin is converted into its active form, psilocin. Psilocin acts mainly on serotonin receptors, especially one called 5-HT2A, which is packed into parts of the brain's outer layer involved in perception, thinking and mood.

The psychedelic experience is thought to involve disrupting the default mode network, a set of brain regions active when we think about ourselves or let the mind wander. Think of it as the mental machinery running in the background when you are not focused on a task, often looping through memories, worries and stories about yourself. In depression, that loop tends to dwell on negative material.

One idea is that psilocybin breaks that loop, and brain imaging supports it. During and after a session, activity in the default mode network drops sharply, and brain regions that rarely talk to each other start communicating more. Participants often describe ego dissolution, a temporary loosening of the rigid sense of self. Some find it freeing; others find it distressing. The therapy uses that window of greater mental flexibility to help reshape entrenched patterns of thought and behavior, with a trained therapist supporting the person before, during and after.

So the drug is never given on its own. Preparation sessions build safety and trust and set expectations. On the dosing day, the person takes psilocybin in a controlled setting with a therapist present throughout, usually for six to eight hours. Integration sessions afterward help the person make sense of the experience and connect any insights to daily life. In this model, drug and therapy are inseparable. Giving psilocybin without that framework is a different treatment from the one the trials test.

The earlier landmark trials, especially COMP360 by COMPASS Pathways and the Johns Hopkins studies, showed efficacy and safety in tightly controlled research settings. They reported large effects: response and remission rates well above placebo, lasting at follow-up longer than most antidepressants manage. What they could not show is whether those results hold when the therapy is delivered inside a public health system, by that system's own therapists, to patients who look like the real treatment-resistant population rather than volunteers who passed extensive screening.

What follows is based on the published abstract. The trial reports a significant benefit of psilocybin-assisted therapy over placebo for treatment-resistant major depressive disorder in a public healthcare setting. Meeting its main goal and appearing in Nature Medicine point to a meaningful, credible result.

The abstract leaves important questions open. It does not say whether the size of the effect matched earlier trials, how often serious side effects occurred, or how these patients differed from research groups. Those answers sit in the full text.

The biggest practical barrier is probably cost. This therapy is labor-intensive: trained therapists, dedicated rooms, several hours per session, and follow-up support. The compound itself is cheap; the therapy is not. Early modeling estimated a full course might cost several thousand dollars per patient in staff and facility time.

A public system with a tight budget has to weigh that against the ongoing cost of depression that never lifts: repeated drug trials, psychiatric hospital stays, disability and lost work. If one or two courses produce lasting remission, the numbers over five or ten years may look very different from the upfront bill. Analyses for related conditions have generally favored psychedelic-assisted therapy on cost-effectiveness, if the efficacy holds. The open question is whether health systems will pay up front, and invest in training and facilities, without knowing for sure how long the benefit lasts.

On safety, the trial record for psilocybin compares well with many psychiatric drugs. There is no established dose at which it is physically toxic to healthy people, and it does not cause dependence. The serious problems seen in trials are almost all psychological: frightening experiences during the session, which the clinical literature calls challenging experiences rather than bad trips, and rarely, brief anxiety or detachment in the days after. Events needing medical care have been very rare. The risks are to the mind, not the body, and the preparation, the therapist's presence and the controlled setting exist to manage them.

Some people should not receive it. Those with a personal or family history of psychosis, or bipolar disorder with psychotic features, are generally excluded because psilocybin can trigger psychotic episodes in vulnerable people. So are people on certain drugs that interact with serotonin signaling. A real clinic will see patients who would have been screened out of research trials, and learning how to handle them takes exactly the kind of real-world data this trial provides.

The legal picture is shifting. Psilocybin remains Schedule I under federal law in the United States, but Oregon legalized supervised psilocybin services in 2023 and Colorado followed. Australia became the first country to allow prescription psilocybin for treatment-resistant depression in 2023. Other places have compassionate use routes. The FDA has given psilocybin for depression breakthrough therapy designation, which speeds review but does not guarantee approval. The rules are moving faster than for any psychedelic in the modern era.

For the people living with it, this is personal, not only clinical. Trying treatment after treatment over years and failing is demoralizing in itself, and treatment-resistant depression carries a heavy weight of hopelessness. Trial reports, and anecdotal accounts from participants, describe a response that feels different from an antidepressant's: not just fewer symptoms but a shift in outlook, a return of meaning, pleasure or connection missing for years. Whether or not standard rating scales capture that, it matters to patients and families.

Becoming a routine option in public health systems would take several things. Regulators in major markets would need to approve it, which requires the full phase 3 submission. Therapists trained in this model would need to exist in far greater numbers than they do now. Facilities would need standards that allow safe sessions without a full research center. Insurers and health systems would need to pay for preparation, session and integration. Each of these takes years.

This trial is a building block, not the finished building. Skeptics of moving research results into practice often point to setting effects: an unusually attentive environment, hand-picked patients and researchers' expectations. A trial run inside a public health system, with real patients and that system's staff, is built to answer that objection directly. It cannot settle every question, but it narrows the gap between what research shows and what a clinician in an ordinary clinic could expect.

The paper is PMID 42562964, published in Nature Medicine on August 6, 2026. This account is based on the published abstract; the full text is behind a paywall.